

#### **ASX ANNOUNCEMENT**

# **Lumos Successfully Completes Institutional Component of Entitlement Offer**

MELBOURNE, Australia (6 September 2024) – Lumos Diagnostics Holdings Limited (ASX: LDX) (Lumos or the Company) is pleased to announce the successful completion of the institutional component of its recently announced A\$10.0 million equity raising, via a 1 for 1.82 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer), with a total of approximately A\$3.1 million from institutional and sophisticated investors. The funds were raised through the institutional component of the Entitlement Offer (Institutional Entitlement Offer), which opened on Wednesday, 4 September 2024 and closed on Thursday, 5 September 2024.

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will raise approximately A\$6.9 million (before costs). The Retail Entitlement Offer is expected to open on Wednesday, 11 September 2024 and close at 5.00pm (AEST) on Wednesday, 2 October 2024.

Shares in Lumos (**Shares**) are expected to recommence trading on an ex-entitlement basis from market open today. The Retail Entitlement Offer is underwritten by the Lead Manager, Bell Potter, with sub-underwriting from Tenmile and Ryder Capital up to approximately A\$6.0 million.

## **Completion of the Institutional Entitlement Offer**

The Institutional Entitlement Offer to raise approximately A\$3.1 million via the issue of approximately 81.7 million new shares was well supported by eligible institutional shareholders.

New shares will be issued at a fixed price of A\$0.038 (3.8 cents) per share and will rank equally with existing shares from allotment. New shares issued under the Institutional Entitlement Offer are expected to settle on Wednesday, 11 September 2024. Commencement of normal trading on the ASX of these new Shares is expected to occur on Thursday, 12 September 2024.

The Company intends to use the proceeds of the Entitlement Offer to fund completion of the FebriDx CLIA waiver trial in the US, product development, sales and marketing activities, working capital purposes and for the costs of the Entitlement Offer.

## **Commencement of Retail Entitlement Offer**

The Retail Entitlement Offer to raise approximately \$6.9 million via the issue of approximately 182.8 million new shares is expected to open on Wednesday, 11 September 2024 and close at 5.00pm (AEST) on Wednesday, 2 October 2024. Eligible Retail Shareholders (defined below) who hold shares in Lumos as at 7:00pm (AEST) on the record date of Friday, 6 September 2024 will be invited to participate in the Retail Entitlement Offer at the same offer price and offer ratio as the participants in the Institutional Entitlement Offer, being \$0.038 (3.8 cents) per share and an offer ratio of 1 for 1.82.

Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer should carefully read the Retail Offer Booklet and accompanying personalised entitlement form, which are expected to be dispatched to Eligible Retail Shareholders on Wednesday, 11 September 2024. The Retail Offer Booklet will provide details of how to participate in the Retail Entitlement Offer. A copy of the Retail Offer Booklet is expected to be lodged with ASX on Wednesday, 11 September 2024.

Shareholders who are eligible to participate in the Entitlement Offer (Eligible Retail Shareholders) are shareholders who:

- are registered as a holder of Shares in the Company as at 7.00pm (AEST) on the Record Date; and
- have a registered address on the Company's share register that is in Australia;
- is not in the US nor acting for the account or benefit of a person in the US or else outside Australia;
- does not hold Shares on behalf of another person who resides outside Australia (unless they hold Shares in another eligible capacity); and
- were not invited to participate in the Institutional Entitlement Offer or treated as an ineligible institutional shareholder for that purpose.

Any Retail Shareholders who are not Eligible Retail Shareholders are **Ineligible Retail Shareholders**. The Company reserves the right to determine whether a Shareholder is an Eligible Retail Shareholder or an Ineligible Retail Shareholder.

### **Key dates for the Entitlement Offer**

Event Event	Date
Record Date for the Retail Entitlement Offer	7:00pm (AEST) on Friday, 6 September 2024
Retail Offer Booklet lodged with the ASX	Wednesday, 11 September 2024
Retail Entitlement Offer opens	Wednesday, 11 September 2024
Settlement of the Institutional Entitlement Offer	Wednesday, 11 September 2024
Allotment of New Shares issued under the Institutional Entitlement Offer	Thursday, 12 September 2024
Commencement of trading of New Shares issued under the Institutional Entitlement Offer	Friday, 13 September 2024
Retail Entitlement Offer closes	5:00pm (AEST) on Wednesday, 2 October 2024
Results of Retail Entitlement Offer announced	Tuesday, 8 October 2024
Settlement of New Shares under the Retail Entitlement Offer	Wednesday, 9 October 2024
Allotment of New Shares issued under the Retail Entitlement Offer	Before 12.00pm (AEST) on Wednesday, 9 October 2024
Commencement of trading of New Shares under the Retail Entitlement Offer	Thursday, 10 October 2024

The timetable above (and each reference to or to dates in this Announcement) is indicative only. The Company, in consultation with the Lead Manager, reserves the right to amend any or all of these dates and times without notice, subject to the Corporations Act,

the Listing Rules and other applicable laws. Any extension of the Closing Date will have a consequential effect on the allotment date of new Shares. The commencement of quotation of the new Shares is subject to confirmation from ASX.

The Company also reserves the right not to proceed with the Retail Entitlement Offer in whole or in part at any time prior to allotment and issue of the new Shares. In that event, the relevant Application Monies (without interest) will be returned in full to Applicants. Cooling-off rights do not apply to an investment in New Shares. You cannot withdraw your Application. Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer are encouraged to submit their Entitlement and Acceptance Form as soon as possible after the Retail Entitlement Offer opens.

#### This announcement is authorised for release by the Lumos Disclosure Committee.

###

#### **About Lumos Diagnostics**

Lumos Diagnostics specialises in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

#### **Media Contacts:**

Haley Chartres – Australia H^CK Director haley@hck.digital +61 423 139 163

## **Investor Contact:**

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

#### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd Level 4, 100 Albert Rd South Melbourne, VIC 3205 info@lumosdiagnostics.com +61 3 9087 1598

#### **Important Notices**

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.